Influence-Tools/republic-os
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

Legal corpus: the complete U.S. Code (59,740 sections, all 53 titles)

Browse Source 
Ingested titles 12–51 and 54 from OLRC USLM XML @119-100 (the whole Code
now, uniform edition; Title 53 is reserved/empty). LegalText 11,221 ->
59,740; repo total 105,704 records. Deterministic (byte-identical rerun,
verified on Title 42's 8,356 sections); make check green. make
legal-us-code default now covers every title.

Co-Authored-By: Claude Opus 4.8 <noreply@anthropic.com>
This commit is contained in:
Fabio
2026-07-06 10:51:44 -04:00
parent 511d65f9a0
commit 76b8ec33a7
48603 changed files with 3677193 additions and 4 deletions
Download Patch File Download Diff File Expand all files Collapse all files
legal/us/code/title-21/chapter-9/section-360dd.md
+35
View File
@@ -0,0 +1,35 @@
---
type: "LegalText"
title: "21 U.S.C. § 360dd"
description: "Open protocols for investigations of drugs for rare diseases or conditions"
jurisdiction: "us"
corpus: "united_states_code"
kind: "code_section"
title_number: 21
title_name: "FOOD AND DRUGS"
chapter_number: "9"
chapter_name: "FEDERAL FOOD, DRUG, AND COSMETIC ACT"
section: "360dd"
citation: "21 U.S.C. § 360dd"
status: "current"
release_point: "119-100"
release_date: "2026-06-26"
source: "official"
source_url: "https://uscode.house.gov/download/releasepoints/us/pl/119/100/xml_usc21@119-100.zip"
source_identifier: "/us/usc/t21/s360dd"
source_file: "data/legal/raw/us/code/title-21/usc21.xml"
source_hash: "66d5be3e5fc6955b7ebcad11c520a0fee70e44d0275a3dc25050f45ac21ce2f9"
raw_snapshot_hash: "3dbd7a61c8616baefb8459bd8dac3b93242106deb416308c8d4dd5a9143176d1"
text_hash: "fcb9052590b854375078b20c886f894f51be8a7181ca35f6b8802798b0e02f71"
retrieved_at: "2026-07-04"
confidence: "official"
tags: ["legal", "us-code"]
---
# 21 U.S.C. § 360dd - Open protocols for investigations of drugs for rare diseases or conditions
## Text
If a drug is designated under section 360bb of this title as a drug for a rare disease or condition and if notice of a claimed exemption under section 355(i) of this title or regulations issued thereunder is filed for such drug, the Secretary shall encourage the sponsor of such drug to design protocols for clinical investigations of the drug which may be conducted under the exemption to permit the addition to the investigations of persons with the disease or condition who need the drug to treat the disease or condition and who cannot be satisfactorily treated by available alternative drugs.
(June 25, 1938, ch. 675, § 528, as added Pub. L. 97–414, § 2(a), Jan. 4, 1983, 96 Stat. 2051.)